Overview

The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)

Status:
Terminated

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to compare two different endpoint measures: heartburn as assessed by the physicians versus gastroesophageal reflux disease (GERD)-related symptoms as assessed by the patient using the ReQuest™ questionnaire. The assessment is made in GERD-patients treated with a daily dose of 40 mg oral pantoprazole over an 8-week period.

Phase:

Phase 4

Details

Lead Sponsor:

Takeda

Treatments:

Pantoprazole